Copy number signatures and CCNE1 amplification reveal the involvement of replication stress in high-grade endometrial tumors oncogenesis

被引:0
|
作者
Marlin, Regine [1 ]
Loger, Jean-Samuel [1 ]
Joachim, Clarisse [2 ]
Ebring, Coralie [3 ]
Robert-Siegwald, Guillaume [4 ]
Pennont, Sabrina [1 ]
Rose, Mickaelle [5 ]
Raguette, Kevin [1 ]
Suez-Panama, Valerie [6 ]
Ulric-Gervaise, Sylviane [1 ]
Lusbec, Sylvie [3 ]
Bera, Odile [1 ]
Vallard, Alexis [7 ]
Aline-Fardin, Aude [8 ]
Colomba, Emeline [9 ]
Jean-Laurent, Mehdi [3 ]
机构
[1] Univ Hosp Martinique, Dept Canc Mol Genet, Fort De France, Martinique, France
[2] Univ Hosp Martinique, Gen Canc Registry Martinique, Fort De France, Martinique, France
[3] Univ Hosp Martinique, Dept Gynecol & Breast Surg, Fort De France, Martinique, France
[4] Univ Angers, MitoVasc Unit, Mitolab Team, SFR ICAT,UMR CNRS 6015,INSERM U1083, Angers, France
[5] Univ Hosp Martinique, Martinique Reg Oncol Platform, Fort De France, Martinique, France
[6] Univ Hosp Martinique, Biol Resource Ctr, Fort De France, Martinique, France
[7] Univ Hosp Martinique, Dept Oncol Hematol Urol, Fort De France, Martinique, France
[8] Cerbapath, Cerba, Martinique, France
[9] Univ Paris Saclay, Inst Gustave Roussy, Dept Canc Med, Gif Sur Yvette, France
关键词
High-grade endometrial cancer; CCNE1; amplification; Replication stress; Copy number signature; SINGLE NUCLEOTIDE POLYMORPHISMS; SOMATIC POINT MUTATIONS; DNA-DAMAGE; TRANSLESION SYNTHESIS; READ ALIGNMENT; CYCLIN E1; TP53; GENE; CANCER; KINASE; GENOME;
D O I
10.1007/s13402-024-00942-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Managing high-grade endometrial cancer in Martinique poses significant challenges. The diversity of copy number alterations in high-grade endometrial tumors, often associated with a TP53 mutation, is a key factor complicating treatment. Due to the high incidence of high-grade tumors with poor prognosis, our study aimed to characterize the molecular signature of these tumors within a cohort of 25 high-grade endometrial cases. Methods: We conducted a comprehensive pangenomic analysis to categorize the copy number alterations involved in these tumors. Whole-Exome Sequencing (WES) and Homologous Recombination (HR) analysis were performed. The alterations obtained from the WES were classified into various signatures using the Copy Number Signatures tool available in COSMIC. Results: We identified several signatures that correlated with tumor stage and disctinct prognoses. These signatures all seem to be linked to replication stress, with CCNE1 amplification identified as the primary driver of oncogenesis in over 70% of tumors analyzed. Conclusion: The identification of CCNE1 amplification, which is currently being explored as a therapeutic target in clinical trials, suggests new treatment strategies for high-grade endometrial cancer. This finding holds particular significance for Martinique, where access to care is challenging.
引用
收藏
页码:1441 / 1457
页数:17
相关论文
共 47 条
  • [31] Coincident expression of β-catenin and cyclin D1 in endometrial stromal tumors and related high-grade sarcomas
    Kurihara, Shuichi
    Oda, Yoshinao
    Ohishi, Yoshihiro
    Kaneki, Eisuke
    Kobayashi, Hiroaki
    Wake, Norio
    Tsuneyoshi, Masazumi
    MODERN PATHOLOGY, 2010, 23 (02) : 225 - 234
  • [32] Inferring transcription activity changes from copy-number and expression data of longitudinally sampled high-grade serous ovarian cancer tumors
    Hakkinen, Antti
    Zhang, Kaiyang
    Hynninen, Johanna
    Hietanen, Sakari
    Huhtinen, Kaisa
    Carpen, Olli
    Lehtonen, Rainer
    Hautaniemi, Sampsa
    CANCER RESEARCH, 2020, 80 (16)
  • [33] Loss of heterozygosity associates with PD-L1 expression and tumor mutational burden in high-grade endometrial tumors
    Mazina, Varvara
    Rueda, Bo
    Eisenhauer, Eric
    Bregar, Amy
    Philp, Lauren
    Watkins, Jaclyn
    Johnstone, Sarah
    Growdon, Whitfield
    GYNECOLOGIC ONCOLOGY, 2022, 165 : S15 - S15
  • [34] Copy number alterations and somatic mutations in primary and recurrent BRCA1-associated high-grade serous ovarian carcinomas
    Raskin, G.
    Bizin, I.
    Gorodnova, T.
    Ivantsov, A.
    Imyanitov, E.
    Sokolenko, A.
    VIRCHOWS ARCHIV, 2019, 475 : S105 - S105
  • [35] NF1 copy number alterations in clinically-defined subsets of high-grade serous ovarian cancers.
    Lee, Sanghoon
    Zhao, Li
    Celestino, Joseph
    Hajek, Richard A.
    Morgan, Margaret B.
    Kim, Mark S.
    Westin, Shannon N.
    Jazaeri, Amir A.
    Fleming, Nicole D.
    Liu, Jinsong
    Zhang, Jianhua
    Futreal, P. Andrew
    Sood, Anil K.
    CANCER RESEARCH, 2021, 81 (13)
  • [36] Mutational and copy number-based ctDNA profiles mirror high-grade serous cancer tumors and enable detection of genetic changes appearing at recurrence
    Marchi, Giovanni
    Nguyen, Mai T. N.
    Rajavuori, Anna
    Muranen, Taru
    Huhtinen, Kaisa
    Oksa, Sinikka
    Hietanen, Sakari
    Hynninen, Johanna
    Oikkonen, Jaana
    Hautaniemi, Sampsa
    CANCER RESEARCH, 2024, 84 (05)
  • [37] Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1-amplification to paclitaxel by targeting APC/C and the pro-survival protein MCL-1.
    Becker, Sven
    Strebhardt, Klaus
    Mandal, Ranadip
    Sanhaji, Mourad
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] Single-cell analysis of copy-number alterations in serous ovarian cancer reveals substantial heterogeneity in both low- and high-grade tumors
    Kumar, Manonmani
    Bowers, Robert R.
    Delaney, Joe R.
    CELL CYCLE, 2020, 19 (22) : 3154 - 3166
  • [39] Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas (vol 69, pg 4036, 2009)
    K-T, Kuo
    Guan, B.
    Feng, Y.
    T-L, Mao
    Chen, X.
    Jinawath, N.
    Wang, Y.
    Kurman, R. J.
    I-M, Shih
    T-L, Wang
    CANCER RESEARCH, 2009, 69 (12) : 5267 - 5267
  • [40] NF1 copy number loss is associated with poorer survival in the homologous recombination deficient subpopulation of high-grade serous ovarian carcinoma
    Stillie, Lorna J.
    Ewing, Ailith
    Meynert, Alison
    Thomson, John P.
    Churchman, Michael
    Herrington, C. Simon
    Roxburgh, Patricia
    Inman, Gareth J.
    Hollis, Robert L.
    Semple, Colin A.
    Gourley, Charlie
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A391 - A391